Upcycling umbilical cords: bridging regenerative medicine with neonatology

References

• WHO. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. WHO; 2011.
   Google Scholar
• Batsali AK, Kastrinaki MC, Papadaki HA, et al. Mesenchymal stem cells derived from Wharton’s jelly of the umbilical cord: biological properties and emerging clinical applications. Curr Stem Cell Res Ther. 2013;8(2):144–155.
   PubMed Web of Science ®Google Scholar
• Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med. 2013;45:e54.
   PubMed Web of Science ®Google Scholar
• Walker PA, Shah SK, Harting MT, et al. Progenitor cell therapies for traumatic brain injury: barriers and opportunities in translation. Dis Model Mech. 2009;2(1–2):23–383.
   PubMed Web of Science ®Google Scholar
• Yu G, Borlongan CV, Stahl CE, et al. Systemic delivery of umbilical cord blood cells for stroke therapy: a review. Restor Neurol Neurosci. 2009;27(1):41–54.
   PubMed Web of Science ®Google Scholar
• Copeland N, Harris D, Gaballa MA. Human umbilical cord blood stem cells, myocardial infarction and stroke. Clin Med. 2009;9(4):342–345.
   PubMed Web of Science ®Google Scholar
• El Omar R, Beroud J, Stoltz JF, et al. Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? Tissue Eng B Rev. 2014;20(5):523–544.
   PubMed Web of Science ®Google Scholar
• Waller-Wise R. Umbilical cord blood: information for childbirth educators. J Perinat Educ. 2011;20(1):54–60.
   PubMedGoogle Scholar
• Acosta SA, Franzese N, Staples M, et al. Human umbilical cord blood for transplantation therapy in myocardial infarction. J Stem Cell Res Ther. 2013.
   Google Scholar
• Roura S, Pujal J-M, Gálvez-Montón C, et al. The role and potential of umbilical cord blood in an era of new therapies: a review. Stem Cell Res Ther. 2015;6(1):123.
   Web of Science ®Google Scholar
• Heidary Rouchi A, Mahdavi-Mazdeh M. Regenerative medicine in organ and tissue transplantation: shortly and practically achievable? Int J Organ Transplant Med. 2015;6(3):93–98.
   PubMed Web of Science ®Google Scholar
• Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317.
   PubMed Web of Science ®Google Scholar
• Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. Stem Cells. 2007;25(11):2886–2895.
   PubMed Web of Science ®Google Scholar
• Moreira A, Kahlenberg S, Hornsby P. Therapeutic potential of mesenchymal stem cells for diabetes. J Mol Endocrinol. 2017;59(3):R109–RR120.
   PubMed Web of Science ®Google Scholar
• Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev. 2006;2(2):155–162.
   PubMed Web of Science ®Google Scholar
• Stavropoulos-Giokas C, Dinou A, Papassavas A. The role of HLA in cord blood transplantation. Bone Marrow Res. 2012;2012:485160.
   PubMedGoogle Scholar
• Wakao S, Kuroda Y, Ogura F, et al. Regenerative effects of mesenchymal stem cells: contribution of muse cells, a novel pluripotent stem cell type that resides in mesenchymal cells. Cells. 2012;1(4):1045–1060.
   PubMedGoogle Scholar
• Sohni A, Verfaillie CM. Mesenchymal stem cells migration homing and tracking. Stem Cells Int. 2013;2013:130763.
   PubMed Web of Science ®Google Scholar
• Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell. 2009;4(3):206–216.
   PubMed Web of Science ®Google Scholar
• Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11–15.
   PubMed Web of Science ®Google Scholar
• Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006;98(5):1076–1084.
   PubMed Web of Science ®Google Scholar
• Arora S, Saha S, Roy S, et al. Role of nonmuscle myosin II in migration of Wharton’s jelly-derived mesenchymal stem cells. Stem Cells Dev. 2015;24(17):2065–2077.
   PubMed Web of Science ®Google Scholar
• Jin F, Hagemann N, Schäfer ST, et al. SDF-1 restores angiogenesis synergistically with VEGF upon LDL exposure despite CXCR4 internalization and degradation. Cardiovasc Res. 2013;100(3):481–491.
   PubMed Web of Science ®Google Scholar
• Cencioni C, Capogrossi MC, Napolitano M. The SDF-1/CXCR4 axis in stem cell preconditioning. Cardiovasc Res. 2012;94(3):400–407.
   PubMed Web of Science ®Google Scholar
• Chen L, Tredget EE, Wu PYG, et al. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3(4):e1886.
   PubMed Web of Science ®Google Scholar
• Baraniak PR, McDevitt TC. Stem cell paracrine actions and tissue regeneration. Regen Med. 2010;5(1):121–143.
   PubMed Web of Science ®Google Scholar
• Huang S, Wu Y, Gao D, et al. Paracrine action of mesenchymal stromal cells delivered by microspheres contributes to cutaneous wound healing and prevents scar formation in mice. Cytotherapy. 2015;17(7):922–931.
   PubMed Web of Science ®Google Scholar
• Lee JW, Fang X, Krasnodembskaya A, et al. Concise review: mesenchymal stem cells for acute lung injury: role of paracrine soluble factors. Stem Cells. 2011;29(6):913–919.
   PubMed Web of Science ®Google Scholar
• Pires AO, Neves-Carvalho A, Sousa N, et al. The secretome of bone marrow and Wharton jelly derived mesenchymal stem cells induces differentiation and neurite outgrowth in SH-SY5Y cells. Stem Cells Int. 2014;2014:438352.
   Google Scholar
• Li J, Li D, Liu X, et al. Human umbilical cord mesenchymal stem cells reduce systemic inflammation and attenuate LPS-induced acute lung injury in rats. J Inflamm. 2012;9(1):33.
   Google Scholar
• Fong CY, Tam K, Cheyyatraivendran S, et al. Human Wharton’s jelly stem cells and its conditioned medium enhance healing of excisional and diabetic wounds. J Cell Biochem. 2014;115(2):290–302.
   PubMed Web of Science ®Google Scholar
• Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579.
   PubMed Web of Science ®Google Scholar
• Hsu YC, Wu YT, Yu TH, et al. Mitochondria in mesenchymal stem cell biology and cell therapy: from cellular differentiation to mitochondrial transfer. Semin Cell Dev Biol. 2016;52:119–131.
   PubMed Web of Science ®Google Scholar
• Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453–R462.
   PubMed Web of Science ®Google Scholar
• Zhang G, Zou X, Miao S, et al. The anti-oxidative role of micro-vesicles derived from human wharton-jelly mesenchymal stromal cells through NOX2/gp91(phox) suppression in alleviating renal ischemia-reperfusion injury in rats. PLoS One. Camussi G, editor. 2014;9(3):e92129.
   PubMed Web of Science ®Google Scholar
• Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10(3):301–312.
   PubMed Web of Science ®Google Scholar
• Liang L, Li Z, Ma T, et al. Transplantation of human placenta-derived mesenchymal stem cell alleviates critical limb ischemia in diabetic nude rat. Cell Transplant. 2017;26(1):45–61.
   PubMed Web of Science ®Google Scholar
• Edwards SS, Zavala G, Prieto CP, et al. Functional analysis reveals angiogenic potential of human mesenchymal stem cells from Wharton’s jelly in dermal regeneration. Angiogenesis. 2014;17(4):851–866.
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu Y, Chen A, et al. Mesenchymal stem cells promote cardiac muscle repair via enhanced neovascularization. Cell Physiol Biochem. 2015;35(3):1219–1229.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Ren H, Han Z. Mesenchymal stem cells: immunomodulatory capability and clinical potential in immune diseases. J Cell Immunother. 2016;2(1):3–20.
   Google Scholar
• Vellasamy S, Tong CK, Azhar NA, et al. Human mesenchymal stromal cells modulate T-cell immune response via transcriptomic regulation. Cytotherapy. 2016;18(10):1270–1283.
   PubMed Web of Science ®Google Scholar
• Prasanna SJ, Gopalakrishnan D, Shankar SR, et al. Pro-inflammatory cytokines, IFNgamma and TNFalpha, influence immune properties of human bone marrow and Wharton jelly mesenchymal stem cells differentially. PLoS One. 2010;5(2):e9016.
   PubMed Web of Science ®Google Scholar
• Leibacher J, Henschler R. Biodistribution, migration and homing of systemically applied mesenchymal stem/stromal cells. Stem Cell Res Ther. 2016;7:7.
   PubMed Web of Science ®Google Scholar
• Sotiropoulou PA, Perez SA, Gritzapis AD, et al. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24(1):74–85.
   PubMed Web of Science ®Google Scholar
• Jacob SV, Coates AL, Lands LC, et al. Long-term pulmonary sequelae of severe bronchopulmonary dysplasia. J Pediatr. 1998.
   PubMed Web of Science ®Google Scholar
• Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells dose-dependently attenuates hyperoxia-induced lung injury in neonatal rats. Cell Transplant. 2011;20(11–12):1843–1854.
   PubMed Web of Science ®Google Scholar
• Ahn SY, Chang YS, Sung DK, et al. Cell type-dependent variation in paracrine potency determines therapeutic efficacy against neonatal hyperoxic lung injury. Cytotherapy. 2015;17(8):1025–1035.
   PubMed Web of Science ®Google Scholar
• Liu L, Mao Q, Chu S, et al. Intranasal versus intraperitoneal delivery of human umbilical cord tissue–derived cultured mesenchymal stromal cells in a murine model of neonatal lung injury. Am J Pathol. 2014;184(12):3344–3358.
   PubMed Web of Science ®Google Scholar
• Sung DK, Chang YS, Ahn SY, et al. Optimal route for human umbilical cord blood-derived mesenchymal stem cell transplantation to protect against neonatal hyperoxic lung injury: gene expression profiles and histopathology. PLoS One. 2015;10(8):e0135574.
   PubMed Web of Science ®Google Scholar
• Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-term and paracrine effect of human umbilical cord-derived stem cells in lung injury prevention and repair in experimental bronchopulmonary dysplasia. Thorax. 2013;68(5):475–484.
   PubMed Web of Science ®Google Scholar
• Chang YS, Choi SJ, Ahn SY, et al. Timing of umbilical cord blood derived mesenchymal stem cells transplantation determines therapeutic efficacy in the neonatal hyperoxic lung injury. PLoS One. 2013;8(1):e52419.
   PubMed Web of Science ®Google Scholar
• Chang YS, Ahn SY, Jeon HB, et al. Critical role of vascular endothelial growth factor secreted by mesenchymal stem cells in hyperoxic lung injury. Am J Respir Cell Mol Biol. 2014;51(3):391–399.
   PubMed Web of Science ®Google Scholar
• Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. J Pediatr. 2014;164(5):966–972.e6.
   PubMed Web of Science ®Google Scholar
• Seaberg RM, van der Kooy D. Stem and progenitor cells: the premature desertion of rigorous definitions. Trends Neurosci. 2003;26(3):125–131.
   PubMed Web of Science ®Google Scholar
• Sirinoglu Demiriz I, Tekgunduz E, Altuntas F, et al. What is the most appropriate source for hematopoietic stem cell transplantation? Peripheral stem cell/bone marrow/cord blood. Bone Marrow Res. 2012;2012:1–5.
   Google Scholar
• Danby R, Rocha V, Gálvez-Montón C. Improving engraftment and immune reconstitution in umbilical cord blood transplantation. Front Immunol. 2014;5:68.
   PubMed Web of Science ®Google Scholar
• Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 2009;44(10):621–626.
   PubMed Web of Science ®Google Scholar
• Douglas-Escobar M, Weiss MD. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatr. 2015;169(4):397–403.
   PubMed Web of Science ®Google Scholar
• Perlman JM. Pathogenesis of hypoxic–ischemic brain injury. J Perinatol. 2007;27:S39–SS46.
   PubMed Web of Science ®Google Scholar
• Zhu L, Bai X, Zhang N, et al. Improvement of human umbilical cord mesenchymal stem cell transplantation on glial cell and behavioral function in a neonatal model of periventricular white matter damage. Brain Res. 2014;1563:13–21.
   PubMed Web of Science ®Google Scholar
• Xia G, Hong X, Chen X, et al. Intracerebral transplantation of mesenchymal stem cells derived from human umbilical cord blood alleviates hypoxic ischemic brain injury in rat neonates. J Perinat Med. 2010;38(2):215–221.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang Q, Li W, et al. Therapeutic effect of human umbilical cord mesenchymal stem cells on neonatal rat hypoxic–ischemic encephalopathy. J Neurosci Res. 2014;92(1):35–45.
   PubMed Web of Science ®Google Scholar
• Kim ES, Ahn SY, Im GH, et al. Human umbilical cord blood–derived mesenchymal stem cell transplantation attenuates severe brain injury by permanent middle cerebral artery occlusion in newborn rats. Pediatr Res. 2012;72(3):277–284.
   PubMed Web of Science ®Google Scholar
• Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility of autologous cord blood cells for infants with hypoxic–ischemic encephalopathy. J Pediatr. 2014;164(5):973–979.e1.
   PubMed Web of Science ®Google Scholar
• Roberts G, Elza S, Ingūna L. Hypoplastic left heart syndrome: a review. Acta Med Lit. 2016;23:86–98.
   PubMedGoogle Scholar
• Yabrodi M, Mastropietro CW. Hypoplastic left heart syndrome: from comfort care to long-term survival. Pediatr Res. 2017 [Accessed: 27 Apr 2017];81(1–2):142–149.
   PubMed Web of Science ®Google Scholar
• Arnold RR, Loukanov T, Gorenflo M. Hypoplastic left heart syndrome – unresolved issues. Front Pediatr. 2014;2:125.
   PubMed Web of Science ®Google Scholar
• Fruitman DS. Hypoplastic left heart syndrome: prognosis and management options. Paediatr Child Health. 2000;5(4):219–225.
   PubMedGoogle Scholar
• Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective Phase 1 controlled trial. Circ Res. 2015;116(4):653–664.
   PubMed Web of Science ®Google Scholar
• Whitelaw A. Core concepts: intraventricular hemorrhage. NeoReviews. 2011;12(2):e94–e101.
   Google Scholar
• Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res. 2010;67(1):1–8.
   PubMed Web of Science ®Google Scholar
• Ahn SY, Chang YS, Sung DK, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013;44(2):497–504.
   PubMed Web of Science ®Google Scholar
• Park WS, Sung SI, Ahn SY, et al. Optimal timing of mesenchymal stem cell therapy for neonatal intraventricular hemorrhage. Cell Transplant. 2016;25(6):1131–1144.
   PubMed Web of Science ®Google Scholar